Computational analysis for identification of the extracellular matrix molecules involved in endometrial cancer progression

Vijesh Kumar Yadav, Tzong-Yi Lee, Justin Bo-Kai Hsu, Hsien-Da Huang, Wei-Chung Vivian Yang, Tzu-Hao Chang

The mechanisms and characteristics of recurrence and distal metastasis of EC remain unclear. The extracellular matrix (ECM) of the reproductive tract in women undergoes extensive structural remodelling changes every month. Altered ECMs surrounding cells were believed to play crucial roles in a cancer progression. To decipher the associations between ECM and EC development, we generated a PAN-ECM Data list of 1516 genes including ECM molecules (ECMs), synthetic and degradation enzymes for ECMs, ECM receptors, and soluble molecules that regulate ECM and used RNA-Seq data from The Cancer Genome Atlas (TCGA) for the studies. The alterations of PAN-ECM genes by comparing the RNA-Seq expressions profiles of EC samples grouped as tumorigenesis and metastasis were identified. Differential analyses including functional enrichment, co-expression network, and molecular network analysis were carried out to identify the specific PAN-ECM genes that may involve in the progression of EC. Eight hundred and thirty-one and 241 PAN-ECM genes were significantly involved in tumorigenesis \( (p\)-value < 1.571e-15) and metastasis \( (p\)-value < 2.2e-16), respectively, whereas 140 genes were in the intersection of tumorigenesis and metastasis. Interestingly, 92 of the 140 intersecting PAN-ECM genes showed contrasting fold changes between the tumorigenesis and metastasis datasets. Enrichment analysis for the contrast PAN-ECM genes indicated pathways such as GP6 signaling, ILK signaling, and interleukin (IL)-8 signaling pathways were activated in metastasis but inhibited in tumorigenesis. The significantly activated ECM and ECM associated genes in GP6 signaling, ILK signaling, and interleukin (IL)-8 signaling pathways may play crucial roles in tumorigenesis and metastasis.
roles in metastasis of EC. Our study provides a better understanding of the etiology and the progression of EC.

Introduction

Extracellular matrix (ECM), a critical component of tissues, is an interlocking mesh of fibrous proteins and polysaccharides including collagen, elastin/nidogen, laminins, and proteoglycans that form a well-organized structure in multicellular organisms [1]. The basic structure of the ECM complex, as described in Fig 1A, provides a supporting structure for cells to anchor [2]. In addition, soluble molecules, such as glycopeptidases and growth factors, are present in spaces among cells and the ECM structure, may regulate cell proliferation, differentiation, and the movement [3], as well as many secreted signaling molecule such as semaphorin III family members genes (SEMA3F) also play a role in Endometrial cancer [4]. The ECM networks and various cytokines and growth factors create a microenvironment for cell growth and development. ECM receptors at the cell surfaces mediate 2-way signals for cells to sense the microenvironment and react to the stimuli [5]. In cancer patients, tumor cells do not grow along, and their behaviors are regulated by their own biology and also by interacting with the surrounding microenvironment [6]. Many components of ECM, like fibrous collagen and elastin create tissue stiffness [7]. Increases in collagen linearization and tissue stiffness in pre-cancerous tissues of breast cancer were reported, and such changes increase the tumor incidence and progression [7]. Proteolysis is a significant factor that leads to metabolic reprogramming of ECM dynamics, and disruption of these control mechanisms causes ECM dysregulation and disorganization, which may contribute to malignant processes or cancer [8, 9]. The ECM paves the way for cancer cell development by creating a favourable microenvironment, more-intense stiffness, etc. [10].

Endometrial cancer (EC) is a commonly occurred malignancy of the female reproductive tract that arises from the uterus lining [11]. While the occurrence of the disease varies widely among countries, EC has become the most common female cancer in areas like North America, Europe, and middle-income developing countries such as South Africa and India [12]. In most cases, women with more-aggressive EC have higher-grade tumors, and the disease spreads from the uterus within 1 year [13]. About 75% of EC patients are diagnosed at an early stage (International Federation of Gynecology and Obstetrics (FIGO) stages I and II) and have an excellent prognosis with a 5-year survival rate of 80% [14, 15]. However, survival rates decrease in severe cases, at 52% and 27% for patients at stages III and IV, respectively [15]. EC is classified into two groups, type I and II endometrioid tumors [16]. Type I is estrogen-dependent [17], obesity is the major risk factor [18], and it has a favourable prognosis; in contrast, type II tumors occur in elderly, non-obese women, are estrogen-independent and exhibit worse outcomes [16, 19]. The most common treatment for patients with EC is surgery combined with adjuvant radiotherapy for early-stage type I EC, and combined with chemotherapy for type II EC [11]. Many studies showed that women with a family history of EC have a higher risk of developing EC in their lifetime [20]. The pathological classification of EC is based on the FIGO system [21, 22]. Stage I cancer is described as the tumor only being found in the uterus or womb and not having spread to other parts of the body. Stage II or beyond is described when a tumor has spread out of the uterus, depending on the migration site and invasion of lymph nodes.
ECM plays a critical role in the female endometrium, being involved in major remodelling changes every month. The ECM of the reproductive tract in women undergoes extensive structural remodelling for decidualization, implantation, and renewal of the endometrial layer each month, while abnormal ECM changes can contribute to processes such as endometriosis, infertility, and cancer development and metastasis [23]. The invasive property is considered as cancer cells intrude into surrounding normal tissues and metastasize. Alterations of ECM, ECM-associated molecules, and the local ECM microenvironment that can promote tumor progression are illustrated in Fig 1. Some of the ECM molecules such as aggrecan, nidogen, collagen type VIII chain α1 and type XI chain α2, were overexpressed in stage III EC [24], matrix metalloproteinase (MMP)-9, an ECM degradation enzyme, might play a vital role in uterine cancer progression [25]. Previous studies by Grabarek B et.al [26] also shows normal human dermal fibroblast cells along with JAK/STAT signaling pathways regulates the
numerous miR’s expression under the influence of adalimumab therapy, indicating ECM molecules can be targeted for treatment effectiveness. However, the regulatory mechanisms of ECM and ECM-associated molecules in EC are still unclear.

The ECM and the ECM associated molecules involved in the microenvironment surrounding the cells seem to play important roles in tumor development; however, a comprehensive analysis of the regulatory mechanisms of ECM during EC development is still lacking. In this study, we attempted to establish a PAN-ECM Data List by collecting ECM and ECM-related genes through a literature survey and incorporation of related databases. Subsequently, we retrieved the gene expression profiles of EC samples at different stages (normal, early, and late) from The Cancer Genome Atlas-Uterine Corpus Endometrial Carcinoma (TCGA-UCEC) data, and used different bioinformatic analysis tools including DESeq2, FunRich, Ingenuity Pathway Analysis (IPA), and Weighted correlation network analysis (WGCNA) to identify and verify the key ECMs and their associates that may participate EC progression. A flow chart and an overview of the computational analysis used in this study was shown in Fig 2.

**Materials and methods**

**Construction of the PAN-ECM Data List**

Through a literature survey (S1 Table) and incorporation of data from related databases (MatrisomeDB; [http://matrisomeproject.mit.edu/](http://matrisomeproject.mit.edu/)) [27], a complete PAN-ECM Data List was generated for further analysis. The Matrisome project provides information on ECM proteins which are collected by computational identification methods, and a proteomics pipeline was developed to characterize compositions of ECM tissues and tumors [28]. However, several essential molecules were lacking, such as ECM-associated regulatory factors (e.g., SMC3), ECM synthetic/degradation enzymes (e.g., UXSI, XYLT1, and XYLT2), cell adhesion molecules (e.g., CDH1 and CD44), ECM microenvironment-associated molecules (e.g., SMAD1 and SMAD7), etc. that were previously identified as playing critical roles in ECM regulation [29–35].

Therefore, we herein focused on developing a complete dataset for ECM research and called it the PAN-ECM Data List. The construction pipeline is depicted in Fig 2A. ECM-associated genes were collected from a literature search using such keywords as cell adhesion molecules, extracellular matrix protein, proteoglycan, collagen, glycoprotein, ECM regulator, ECM micro-environment associated, proteoglycans and secreted factors, etc. Additionally, ECM genes in MatrisomeDB were also integrated into the PAN-ECM Data List, and their functions were annotated from functional annotation databases including Gencard.

**EC data collection and analysis of differentially expressed genes (DEGs)**

**Inclusion and exclusion criteria for UCEC sample and the classification of DEGs.** The RNA-Seq level 3-gene expression data for normal and solid tumors from UCEC patients were collected from TCGA [36] (Broad GDAC Firehose database: [http://firebrowse.org/?cohort=UCEC](http://firebrowse.org/?cohort=UCEC)). In total, 35 normal samples, and 476 tumor samples were used for this study. Based on FIGO staging for endometrial carcinoma, the tumor samples at stage IA was classified as early-stage samples, samples obtained from patients at stage II and above were classified as late-stage samples. In this study, 159 samples were late-stage and 317 samples were early-stage samples. Based on the description of the pathology in FIGO staging, EC tumors at stage IB has ≥ 50% invasion of the myometrium. To avoid the interferences, the data from the samples at stage IB patient was excluded in this study.

Both raw read counts and normalized fragments per kilobase of transcripts per million mapped reads (FPKM) values (FPKM-UQ) at the gene level were used for further analysis.
Clinical XML files were also downloaded to retrieve stage and related clinical information, which was used to recognize tumorigenesis and metastasis samples, as explained in FIGO guidelines [21, 22]. Tumorigenesis DEGs were identified by comparison the DEGs from early-stage (stage IA) to normal samples, and metastatic DEGs were identified by comparing the DEGs from late-stage (stage II or above) to early-stage EC samples (stage IA).

**Statistical analysis.** Expression data were pre-processed and analyzed using DESeq2, an R package [37], and log2 fold change cutoffs of >1.5 and adjusted p values of <0.01 were used to determine significant DEGs. With thousands of genes tested in an RNA-Seq, multiple comparison adjustments were necessary. The Bonferroni method was applied for filtering DEGs; this controls the mean number of false positives, that can be used for multiplicity adjustment [38]. Samples at different stages were taken for a comparative analysis to identify tumorigenesis- and metastasis-associated DEGs during EC development, as illustrated in Fig 2B. A Chi-squared test was applied to test whether ECM genes were significantly associated with EC tumorigenesis or metastasis.
Analysis of ECM regulatory mechanisms during EC development

To identify potential functions and regulatory roles of the ECM during EC development, as shown in Fig 2C, three different network analytical approaches were applied: a canonical pathway network analysis, molecular interaction network analysis, and co-expression network analysis. The canonical pathway network analysis was performed by using an Ingenuity Pathway Analysis (IPA) [39], that uses the popular activation z-score analytical method. It was proposed by Kraemer et al. in 2014 [39], and it measures activation states, (either increased or decreased) of pathways affected by DEGs. We used a statistical approach to define a quantitative z-score, which determines whether a biological function has significantly more “increased” predictions than “decreased” predictions (z-score >0) or vice versa (z-score <0). In general practice, an absolute z-score of >2 or < -2 may be significant. A molecular interaction network analysis was performed using FunRich [40] to generate networks based on predicted or experimentally validated interactions, such as protein-protein interactions and gene-gene regulation to identify critical ECM-involved networks or critical ECM hub genes. The coexpression network analysis was performed using WGCNA, an R package [41], for EC samples. The BlockwiseModules function was applied to construct gene coexpression hierarchical clustering, and dynamic tree cut methods were used to identify co-expression networks.

Results

PAN-ECM Data List

Based on a literature survey, a list of ECM and ECM-associated molecules including 1516 ECM-related genes, called as PAN-ECM Data List was generated (S1 Table). The PAN-ECM genes were then classified into 15 categories according to their biological functions and localizations: cell surface receptors, cytoskeleton, cell adhesion molecules, collagens, ECM receptor cofactors, ECM receptors, ECM, ECM-associated regulatory factors, ECM synthetic/degradation enzymes, ECM-affiliated proteins, ECM glycoproteins, ECM regulators, ECM microenvironment-associated, proteoglycans, and secreted factors. Numbers of genes in different categories of the PAN-ECM Data List are given in Fig 3.

Tumorigenesis and metastasis DEG analysis

Total of 20,531 DEGs from EC patients was retrieved from TCGA. Background distribution of 1516 PAN-ECM genes in a total of 20,531 DEGs is 7.38%. Based on FIGO staging for endometrial carcinoma development, we investigated the expression level of the DEGs and classified the DEGs from normal endometrium as the normal group, the DEGs from EC samples at stage IA as an early-stage group, DEGs from EC samples at stage II and the above as late-stage group. By comparing the expression level, 7880 DEGs were considered to be tumorigenesis-associated (early vs. normal) and 1677 DEGs were metastasis-associated (late vs. early), respectively. In those tumorigeneses- and metastasis-associated DEGs, 831 (S2 Table) and 241 (S3 Table) DEGs were PAN-ECM genes, respectively. Interestingly, the 831 tumorigenesis-associated PAN-ECM genes of 7880 DEGs (10.54%, Chi-squared p < 1.571e-15) and the 241 metastasis-associated PAN-ECM genes of 1677 DEGs (14.37%, Chi-square p < 2.2e-16) were significant, as compared to the background distribution of 7.38% in the total of 20,531 DEGs. Detailed information about fold change values in correlation with tumorigenesis and metastasis and the list of 140 intersecting PAN-ECM DEGs were shown in Table 1. These PAN-ECM genes were separated into four different categories according to their fold changes as up/up (37 genes), up/down (35 genes), down/up (57 genes), and down/down (11 genes) in tumorigenesis and metastasis, respectively. It indicates that 48 PAN-ECM genes were either up/up or
down throughout all stages during EC development, whereas 92 PAN-ECM genes were expressed in contrasting direction of fold change (up/down or down/up) at tumorigenesis and metastasis stages.

Pathway analysis of tumorigenesis- and metastasis-related PAN-ECM genes

IPA was applied for pathway analysis for the identified EC-associated PAN-ECM genes (Fig 4A). Numerous signaling pathways associated with the 140 intersecting PAN-ECM DEGs were identified (Fig 4B). The identified pathways included GP6 signaling, IL-8 signaling, ILK...
Table 1. The expression of 140 intersecting PAN-ECM DEGs in EC at tumorigenesis and metastasis stages.

| Up/Up Genes (37) (FC_T, FC_M) | Up/Down Genes (35) (FC_T, FC_M) | Down/Up Genes (57) (FC_T, FC_M) | Down/Down Genes (11) (FC_T, FC_M) |
|-------------------------------|---------------------------------|---------------------------------|---------------------------------|
| ATP1A3 (1.30, 1.17) | ADAM28 (1.16, -0.72) | ADAM33 (-2.54, 1.05) | LOXL4 (-1.91, 0.59) |
| C1QL1 (1.62, 1.27) | ADAMT36 (1.41, -1.09) | ADAMT31 (-2.36, -0.61) | MAG (-4.30, 1.48) |
| C1QL4 (4.78, 0.90) | ADAMTSL2 (1.41, -0.70) | ADAMT53 (-2.22, 1.41) | MEGF10 (-1.87, 1.03) |
| CAMK2N2 (1.76, 0.77) | BMPR1B (1.04, -0.59) | ADAMTSL4 (-2.36, 0.59) | NCAM1 (-4.28, 1.21) |
| CCL7 (1.53, 0.84) | CCL24 (2.69, -1.37) | AGTR1 (-4.45, 1.49) | NELL2 (-1.89, 0.92) |
| COL10A1 (1.42, 1.42) | CELA3A (3.42, -1.07) | ANGPT1 (-2.62, 1.06) | NTF4 (-3.87, 1.82) |
| COL11A1 (2.44, 0.99) | CELA3B (2.05, -0.88) | ANGPTL7 (-2.52, 1.30) | PAPLN (-0.84, 0.85) |
| COL11A2 (1.46, 0.98) | CST1 (6.09, -1.15) | CADM3 (-3.20, 1.09) | PCOLCE2 (-2.53, 0.83) |
| COL26A1 (4.72, 0.88) | CST4 (6.22, -1.96) | CCL11 (-1.74, 0.82) | POSTN (-2.72, 0.60) |
| COL9A1 (3.51, 1.90) | CTSV (5.15, -0.77) | CHRD (-1.70, 0.94) | PRL (-1.52, 0.96) |
| COMP (1.85, 2.00) | DMBT1 (3.05, -1.43) | CHSY3 (-1.18, 0.63) | RELN (-1.98, 1.13) |
| CRLF1 (1.32, 0.63) | FBLN1 (1.13, -0.68) | COL19A1 (-1.18, -0.62) | SGCG (-1.13, 0.94) |
| DCSTAMP (1.28, 0.60) | GAD1 (5.24, -0.89) | COL20A1 (-2.10, 1.51) | SEMA6D (-2.26, 0.73) |
| EGF6 (1.92, 0.66) | GDF5 (3.84, -1.05) | COL4A4 (-1.88, 1.67) | SRPX (-3.80, 0.82) |
| ERBB2 (0.60, 0.73) | HHIP (1.68, -0.62) | COL6A3 (-2.20, 0.80) | SYT1 (-3.47, 0.77) |
| EREG (2.84, 0.84) | IHH (2.89, -1.52) | COL6A6 (-2.89, 1.26) | TGM1 (-1.48, 0.72) |
| F2 (2.89, 0.77) | IL9 (4.92, -0.89) | COL8A2 (-1.13, 0.91) | THBS2 (-2.14, 0.65) |
| FGFR4 (1.83, 0.61) | ITIH2 (2.00, -0.86) | CRHBPP (-4.00, 0.64) | TLL1 (-2.59, 0.63) |
| FZD9 (1.49, 0.81) | LMAN1 (3.55, -1.15) | DNM3 (-1.10, 0.67) | TPO (-2.49, 0.94) |
| IL11 (2.52, 1.21) | MATN1 (1.04, -0.65) | EYS (-0.79, 0.67) | WIFKKN2 (-2.37, 0.92) |
| INHBE (1.30, 0.62) | MMP26 (2.47, -3.07) | FAP (-2.45, 0.69) | |
| ITGB6 (2.12, 0.92) | MUC13 (2.62, -0.88) | FN1 (-1.05, 0.79) | |
| KCP (1.75, 0.70) | MUC5AC (6.62, -0.90) | FREM1 (-2.34, 0.62) | |
| LIF (1.46, 1.24) | MUC5B (4.57, -1.13) | FSTL3 (-1.43, 0.60) | |
| MATN4 (1.92, 0.62) | PF4V1 (4.66, -1.07) | GDF6 (-2.56, 1.05) | |
| MMP1 (4.57, 1.05) | PLA2G10 (2.46, -0.72) | GREM1 (-2.92, 0.77) | |
| MMP10 (3.71, 1.14) | BDNF (1.63, -1.76) | HGF (-2.38, 0.60) | |
| MMP13 (4.07, 1.12) | S100A3 (2.23, -0.61) | HPSE (-1.08, 0.66) | |
| PRSS1 (3.87, 1.34) | S100A7 (5.31, -1.33) | IGF10 (-2.65, 0.69) | |
| PRSS3 (2.75, 1.01) | SEMA3E (2.18, -0.84) | IL5 (-1.53, 1.00) | |
| RSP04 (1.73, 1.28) | SERPINA11 (4.81, -1.87) | IL6 (-2.88, 1.51) | |
| SFTPB (2.76, 1.08) | NTF3 (1.43, -1.18) | IMPG2 (-3.78, 0.86) | |
| SLIT1 (1.25, 0.59) | TNFSF14 (1.29, -0.79) | ISM2 (-1.86, 0.78) | |
| SST (3.72, 2.93) | TPH1 (1.79, -0.84) | ITGB3 (-1.54, 1.02) | |
| TMRPSS15 (2.33, 0.99) | WIFI (2.75, -1.06) | ITLN1 (-1.70, 0.87) | |
| TNF (2.55, 0.61) | LAMA2 (-3.10, 0.68) | | |
| WNT7A (3.64, 0.97) | LGI2 (-3.55, 1.07) | | |

Total of 140 intersecting PAN-ECM genes were identified and grouped as Up/Up, Up/Down, Down/Up, Down/Down expression in EC at tumorigenesis and metastasis stages respectively.

*Number of genes.
*The fold change of DEGs in tumorigenesis (FC_T).
†the fold change of DEGs in metastasis (FC_M).

https://doi.org/10.1371/journal.pone.0231594.t001
signaling, neuroinflammation signaling pathway, colorectal cancer metastasis signaling, leukocyte extravasation signaling, and osteoarthritis pathway.

Interestingly, several signalling pathways were expressed in opposite fold changes at tumorigenesis and metastasis stages. GP6 signaling pathway was inhibited with the lowest z-score (-0.832) in tumorigenesis but activated in metastasis with the highest z-score (3.605). IL-8 signaling (z-score = -1), ILK signaling (z-score = -1), and neuroinflammation signaling pathways (z-score = -0.447) were also inhibited at tumorigenesis, but activated in metastasis. Moreover, pathways such as colorectal cancer metastasis signaling (z-score = 1.133 in tumorigenesis and 1.889 in metastasis), leukocyte extravasation signaling (z-score = 1 and 1), and osteoarthritis (z-scores = 0.447 and 1.341) were activated at both tumorigenesis and metastasis stages.

Pathway analyses were also carried out for the identified tumorigenesis and metastasis-associated PAN-ECM genes, detailed canonical pathways generated from 831 tumorigenesis- and 241 metastasis-associated PAN-ECM genes were shown in S1 Fig. Notably, GP6 signaling pathway had the highest z-score (4.14) in the metastasis-associated PAN-ECM genes and the lowest z-score (-1.414) in the tumorigenesis-associated PAN-ECM genes, that resembles the results from the analyses for the intersecting PAN-ECM genes. The PAN-ECM genes involved in the GP6 signaling pathway were listed in Fig 5. The PAN-ECM genes including COL4A4, COL6A6, ITGB3, PI3K, and αIIbβ3 in GP6 signaling pathway were upregulated in metastasis and downregulated in tumorigenesis.

---

Fig 4. Diagram of the intersecting PAN-ECM genes and their involved canonical pathways in association with tumorigenesis and metastasis of EC by IPA analysis. (a) The diagram shows the PAN-ECM genes in the intersection between tumorigenesis and metastasis. (b) The heat map represents the intersecting PAN-ECM gene involved canonical pathways and their expressions in tumorigenesis and metastasis of EC. The orange color indicates activation of functions/pathways, blue color indicates inhibition of functions/pathways. Intensive color indicates higher absolute z-score.

https://doi.org/10.1371/journal.pone.0231594.g004
Functional enrichment analysis of tumorigenesis- and metastasis-associated DEGs

To depict the possible roles of the intersecting PAN-ECM genes in tumorigenesis and metastasis of EC, the disease-related and bio functions of the DEGs from IPA were enumerated in
Table 2. Diseases and bio-functions of the intersecting PAN-ECM genes associated with differential expressions in tumorigenesis and metastasis of EC.

| Diseases and bio-functions                                                                 | Tumorigenesis (z-score) | Metastasis (z-score) |
|------------------------------------------------------------------------------------------|-------------------------|----------------------|
| Cardiovascular system development and function: cell movement of endothelial cells        | -2.116                  | 0.761                |
| Cellular growth and proliferation: colony formation of cells                              | -1.377                  | 2.021                |
| Cell death and survival, hematological system development and function: cell viability of myeloid cells | -1.217                  | 2.177                |
| Cellular movement, hair and skin development and function: cell movement of epithelial cell lines | -1.05                   | 2.418                |
| Cellular movement: migration of cells                                                     | -0.755                  | 3.864                |
| Cell-to-cell signaling and interaction, hematological system development and function, immune cell trafficking: adhesion of immune cells | -0.487                  | 2.381                |
| Cellular development, cellular growth and proliferation: proliferation of myeloma cell lines | -0.478                  | 2.146                |
| Free radical scavenging, small molecule biochemistry: biosynthesis of hydrogen peroxide  | -0.462                  | 2.202                |
| Cellular development, cellular growth and proliferation: proliferation of prostate cancer cell lines | -0.349                  | 2.195                |
| Post-translational modification: phosphorylation of proteins                              | -0.34                   | 3.06                 |
| Cell-to-cell signaling and interaction, cellular growth and proliferation: induction of cells | -0.232                  | 2.201                |
| Proliferation of connective tissue cells                                                  | -0.194                  | 2.391                |
| Cellular growth and proliferation, connective tissue development and function, tissue development | -0.128                  | 2.402                |
| Lipid metabolism, small molecule biochemistry: synthesis of leukotriene                    | -0.111                  | 2.352                |
| Cellular movement: invasion of cells                                                     | 0                       | 2.138                |
| Cell-to-cell signaling and interaction, hematological system development and function: binding of lymphocytes | 0.068                   | 3.174                |
| Cellular movement: invasion of tumor cell lines                                           | 0.113                   | 2.72                 |
| Cell-to-cell signaling and interaction, hematological system development and function: binding of mononuclear leukocytes | 0.119                   | 2.584                |
| Cell-to-cell signaling and interaction: binding of myeloid cells                          | 0.221                   | 2.697                |
| Cellular growth and proliferation, tissue development: proliferation of epithelial cells   | 0.528                   | 4.022                |
| Cellular movement: migration of ovarian cancer cell lines                                 | 0.577                   | 2.194                |
| Cell signaling, molecular transport, small molecule biochemistry, vitamin and mineral metabolism: release of Ca2+ | 0.603                   | 3.046                |
| Cellular development, cellular growth and proliferation: proliferation of stem cells       | 0.672                   | 2.167                |
| Cell-to-cell signaling and interaction: binding of lymphoma cell lines                    | 0.757                   | 2.366                |
| Cell signaling, molecular transport, vitamin and mineral metabolism: quantity of Ca2+    | 1                       | 2.387                |
| Cell death and survival: apoptosis of gonadal cells                                       | 1.076                   | 2.19                 |
| Cellular growth and proliferation: expansion of cells                                    | 1.258                   | 2.01                 |

Activated pathways are coloured orange (z-score >2) and inhibited pathways are coloured blue (z-score < -2). The absolute z-score is higher, the color is more intensive.

https://doi.org/10.1371/journal.pone.0231594.t002

Table 2. Interestingly, the most correlated bio functions, cell movement, colony formation, cell proliferation, cell migration, adhesion of immune cells, and invasion of cells were activated with higher z-scores (>2) in metastasis and inhibited in tumorigenesis with lower z-scores (< -2). The bio functions, such as cell death and survival, cell-to-cell signaling, proliferation of epithelial cells, cellular growth, and cell cycle mitogenesis, were activated in both metastasis and tumorigenesis of EC. It suggested that the differential activation and inhibition of the bio functions of the PAN-ECM genes may lead to EC progression.

Network analysis of intersecting PAN-ECM genes between tumorigenesis and metastasis DEGs

To decipher the possible regulatory mechanisms of the ECM involved microenvironment during EC development, a molecular interaction network was generated by applying the 140 intersecting PAN-ECM genes using FunRich analysis. The generated network is shown in Fig 6. Each network consists of connected PAN-ECM genes with a hub gene. As indicated, hub
genes with the most intensive connections were \( \text{FN1} \), \( \text{ITGB3} \), \( \text{ERBB2} \), and \( \text{BMPR1B} \). In addition, the hub genes with the contrasting fold change in tumorigenesis and metastasis included \( \text{100A7} \), \( \text{FBLN1} \), \( \text{SERPINAS} \), \( \text{TNFSF14} \), \( \text{BMPR1B} \), and \( \text{GDF5} \), which were upregulated in tumorigenesis and downregulated in metastasis, and \( \text{FSTL3} \), \( \text{ADAMTS1} \), \( \text{COL4A4} \), \( \text{HGF} \), \( \text{MAG} \), \( \text{FN1} \), \( \text{ITGB3} \), \( \text{NCAM1} \), \( \text{AGTR1} \), and \( \text{DNM3} \), which were downregulated and upregulated in tumorigenesis and metastasis, respectively.

**Gene coexpression network analysis**

The gene coexpression network was constructed using the retrieved 20,531 genes from EC tumor samples using a systematic unsupervised method, WGCNA. As shown in Fig 7A, numerous modules were generated, whereas four modules consisting of the highest proportions of PAN-ECM genes, ranging 11%~52%, were selected for further analyses Fig 7B. Significantly involved pathways among the modules are enumerated in Table 3.

As described previously, high grade and re-occurred EC have poor prognosis outcome. Therefore, we attempted to dig the possible mechanisms and the characteristics of the ECM microenvironment during high-grade EC at metastasis stage. The pathway analyses for metastasis-associated PAN-ECM genes listed in Table 3 showed that module 1 and 2 possessed the
highest proportions (52% and 30% respectively) of PAN-ECM genes, where those PAN-ECM genes are involved in three pathways, GP6 signaling, dendritic cell maturation, and osteoarthritis pathways, suggesting that those PAN-ECM genes and their involved pathways may play crucial roles during EC metastasis.

In addition, colorectal cancer metastasis signalling, IL-6 signaling, and IL-8 signaling also were also predicted to be activated during EC metastasis, whereas RhoGDI signaling pathway was predicted to be inhibited in metastatic EC. The molecular network of coexpression module 1 containing the highest proportion of PAN-ECM genes including COL1A1, BGN, NID1, ADAM12, COL1A2, INHBA, THBS1, SPARC, FBN1, and CSPG4 was shown in Fig 7C. The typical metastasis-associated hub genes were identified.

**Discussion**

In this study, PAN-ECM Data List was generated, that covers not only ECMs, but also synthetic and degradation enzyme for ECMs and ECM associated molecules and the regulators, also present in the extracellular microenvironment surrounding cells. The PAN-ECM Data List has a total of 1516 ECMs and ECM-associated genes. Comparison to the Matrisome Project [28], there were 489 additional genes that contribute in 9 categories including cell surface receptor, cytoskeleton, cell adhesion molecules, ECM receptor cofactors, ECM receptors, ECM membrane-associated, ECM-associated regulatory factors, ECM synthetic/degradation enzymes, and ECM microenvironment associated. Some of the genes were reported to be involved in many critical biological processes, for instance, integrin subunit alpha 2b (ITGA) and intercellular adhesion molecule 1 (ICAM1) genes, which is an ECM receptor and a
molecule that can bind to integrin, respectively, both play crucial roles in tumor development [42]. In addition, the cell surface receptor category includes transforming growth factor-beta receptor genes (TGFBR1 and TGFBR3), and that the elevated TGFBR levels could induce collagen expression in metastatic breast cancer cells [43]. Several genes in the cell adhesion molecule category, such as CD44 and CADM1, were involved in cancer cell migration and the regulation of ECM adhesion [44, 45]. ITGB3 and BMPR2 genes were key regulators of cell migration and invasion of cancer cells [46, 47]. XLYT1 in ECM synthetic/degradation enzymes play important roles in the initiation step of the biosynthesis of glycosaminoglycan [48]. Differential expression of XDH gene modulated the migration of human breast cancer cells [49].

One forty ECM and ECM-associated genes have been identified, that may participate in tumorigenesis and metastasis of EC. Numerous identified genes have been reported to participate in the development of other cancers, for instance, COL11A1, MMP1, COL10A1, HHIP, and COL6A6 could be prognostic and predictive indicators of early-stage non-small cell lung cancer (NSCLC) [50]; upregulation of ITBG3 and COL4A3 genes could respectively promote colorectal cancer and breast cancer development [51, 52]. Alterations of EGFL6 associated with metastasis of ovarian cancer [53].

**Table 3. Gene clustering of the metastasis-associated PAN-ECM differentially expressed genes (DEGs) by WGCNA module analysis.**

| Canonical pathway (IPA Knowledgebase database) | Metastasis PAN-ECM (241*) (z-score) | Module 1 (77) (z-score*) | Module 2 (74) (z-score*) | Module 3 (164) (z-score*) | Module 4 (253) (z-score*) |
|-----------------------------------------------|----------------------------------|---------------------------|---------------------------|---------------------------|---------------------------|
| GP6 signaling pathway                         | 4.15                             | 2.11                      | 1.41                      | 0.00                      | 0.00                      |
| Dendritic cell maturation                     | 2.45                             | 2.24                      | 2.45                      | 0.00                      | 0.90                      |
| Osteoarthritis pathway                       | 2.31                             | 1.34                      | 0.45                      |                           |                           |
| Colorectal cancer metastasis signaling       | 2.89                             |                           |                           |                           |                           |
| Wnt/β-catenin signaling                      | 2.45                             | 2.14                      |                           |                           |                           |
| Neuroinflammation signaling pathway          | 2.45                             | 0.00                      | 1.73                      | 0.00                      | 0.30                      |
| ILK signaling                                | 2.45                             |                           |                           |                           |                           |
| Role of pattern recognition receptors in recognition of bacteria and viruses | 2.24                             | 0.00                      | 2.45                      | 0.00                      | 0.38                      |
| Neuregulin signaling                         | 2.24                             | 0.00                      | 2.24                      | 0.00                      |                           |
| Signaling by Rho family GTPases              | 2.00                             | 0.00                      | 2.53                      | 0.00                      |                           |
| IL-6 signaling                               | 2.00                             |                           | 3.00                      |                           |                           |
| ErbB signaling                               | 2.00                             | 0.00                      | 2.71                      | 0.00                      |                           |
| Growth hormone signaling                     | 2.00                             | 0.00                      | 2.65                      |                           |                           |
| Glioblastoma multiform signaling             | 1.89                             |                           | 2.71                      |                           |                           |
| Leukocyte extravasation signaling            | 1.63                             |                           | 2.53                      |                           | -1.67                     |
| HMGBl signaling                              | 1.41                             | 0.00                      | 2.83                      |                           |                           |
| IL-8 signaling                               | 1.34                             | 0.00                      | 3.46                      | -1.00                     | -0.71                     |
| Role of NFAT in cardiac hypertrophy          | 1.34                             |                           | 2.71                      |                           |                           |
| eNOS signaling                               | 1.00                             | 0.00                      | 2.65                      |                           |                           |
| FGF signaling                                | 0.82                             | 0.00                      | 2.65                      | 0.00                      |                           |
| Acute-phase response signaling               | 0.45                             |                           | 2.45                      |                           |                           |
| Gît12/13 signaling                           | -0.45                            | 0.00                      | 3.00                      |                           |                           |
| RhoGDI signaling                             | -1.00                            |                           | -1.34                     |                           |                           |
| LXR/RXR activation                           | -1.00                            | 0.00                      | 0.00                      | 0.00                      | 0.45                      |

The canonical pathways involved in each modules was listed and sorted by z-score.

*Number of genes.

https://doi.org/10.1371/journal.pone.0231594.1003
Interestingly, several PAN-ECM genes involved signaling pathways, GP6 signaling pathway, ILK signaling pathway, and IL-8 signaling pathway were significantly inhibited in tumorigenesis and activated in metastasis of EC, suggesting that those specific PAN-ECM genes may participate in EC metastasis and progression. To our knowledge, PAN-ECM gene involved GP6 signaling in association with EC progression has not been reported. GP6, a glycoprotein, is mainly expressed in platelets. GP6 signaling pathway was primarily thought to participate in platelets and their precursor megakaryocyte activation [54]. Aggregation of platelets may shield circulating tumor cells from immunosurveillance and to promote tumor progression and metastasis [55]. Another report suggested that GP6 served as the primary signaling receptor for collagen, which induces platelet activation and thrombus formation [54]. Defect of GP6 could cause malfunction of platelet reactivity to collagens in blood and lung cancer metastasis [56, 57]. An elevated level of serum platelets lowered the chemotherapy response rate and increased the risk of recurrence in EC [58]. Our current study identified several collagen genes that were upregulated in metastatic EC, suggesting that the upregulated collagens may activate GP6 signaling and protect the EC cells from immunosurveillance and promote tumor metastasis.

ILK signaling pathway was shown to represent an essential kinase activity and also regulated the decidualization of endometrial stromal cells [59]. It also played a role in hormone-dependent cancer progression and regulated a variety of cellular functions including cell survival, migration, and angiogenesis, its gain or loss of function resulted in oncogenic transformation and progression of invasive and metastatic phenotypes [60]. IL-8 signaling belongs to CXC chemokine family. Many studies confirmed high levels of IL-8 in HER2-enriched and basal-like (ER−) primary breast cancer, whereas patients with a low level of IL8 had better prognosis [61].

The hub gene they interact with the other PAN-ECM genes may play crucial roles in regulating the EC development and the progression. From the molecular network analysis (Fig 6), we identified several hub genes, such as FN1, ITGB3, and BMPR1B, interacted with the other ECM molecules intensively. These genes were associated with many critical biological functions related to cancer cell metastasis. FN1 was previously reported to be associated with adverse or poor prognosis of breast and ovarian cancer [62]. Increased expression of ITGB3 could promote and control the metastasis of breast cancer and EC [63, 64]. BMPR1B was correlated with cell proliferation, suggesting that it may play a role in protecting against endometriosis progression [65]. A previous study by Frida et al.’s team explained the transformation of normal cells to malignant and metastatic tumor cells. VCAN, an ECM gene was initially downregulated but upregulated in metastasizing cells in the prostate and colorectal cancers [66]. Our results showed that the metastatic EC associated ECM genes were highly expressed at a late stage and might participate in EC progression.

From the coexpression network analysis identified several modules possessing higher proportions of ECM genes. Interestingly, the GP6 signaling pathway along with the dendritic cell maturation and osteoarthritis pathways were activated in modules 1 and 2 and in metastatic DEGs (Table 3). Notably, GP6 signaling was identified not only by functional enrichment analysis but by coexpression network analysis. PAN-ECM genes, such as COL1A1, COL1A2, BGN, NID1, ADAM12, INHBA, THBS1, SPARC, and CSPG4, were identified to act as hub genes. Increased expressions of COL1A1 and COL1A2 were associated with lower survival of ovarian cancer patients [67]. BGN gene could enhance migration and invasion of EC [68]. NID1 gene was found to be a new therapeutic target biomarker in breast cancer and EC invasion [69]. ADAM12 was a tumor marker and has negative prognostic value for overall survival in ovarian cancer [70]. Strong colocalization of INHBA was highly associated with malignant endometrial tissues [71]. THBS1 expression might associate with the survival of EC
patients [72]. Overexpression of *SPARC* gene could promote migration of EC [73]. Increased expression of *CSPG4* gene was correlated with disease reappearance in patients with breast cancer [74].

Increased matrix stiffness has a profound effect on tumor development and progression [75]. Upregulation of collagen and integrins is known to participate in stiffness [76, 77]. Increased matrix stiffness resulted in increases in cell outgrowth and sprouting, which were correlated with cancer metastasis [78]. Collagen expressions, mainly types I, III, and VI, have been studied in the past few years, and higher expressions of those ECM genes were positively correlated with matrix stiffness [27, 79–81]. In this study, many collagen-associated genes, such as *COL4A4*, *COL19A1*, and *COL6A6* (Table 1), showed decreased expressions at early stages and increased expressions at the late stage of EC. These findings suggested that those ECM genes may participate in EC progression.

**Conclusions**

In this work, we compiled a comprehensive PAN-ECM Data List including ECM and ECM-associated genes. The ECM genes including collagens and integrins and the signaling pathway, GP6, ILK signaling, and IL-8 signaling pathways, were highly correlated with metastatic EC. The identified PAN-ECM genes and their participated signaling pathways may lead to the development of novel biomarkers and new therapeutic strategies for the re-occurred, poor prognosis of high-grade EC.

**Supporting information**

S1 Fig. Ingenuity Pathway Analysis (IPA) of tumorigenesis- and metastasis-associated PAN-ECM gene involved canonical pathways. (a) List of tumorigenesis-associated PAN-ECM gene involved canonical pathways (b) List of metastasis-associated PAN-ECM gene involved canonical pathways. Orange color indicates activated pathways with positive z-scores. Blue color indicates inhibited pathways with negative z-scores. The color is darker indicate the absolute z-score is higher.

(DOCX)

S1 Table. Complete PAN-ECM Data List with PUBMED ID (1516).

(DOCX)

S2 Table. Tumorigenesis PAN-ECM DEGs (831 genes).

(DOCX)

S3 Table. Metastasis PAN-ECM DEGs (241).

(DOCX)

**Author Contributions**

**Conceptualization:** Wei-Chung Vivian Yang, Tzu-Hao Chang.

**Data curation:** Vijesh Kumar Yadav, Tzong-Yi Lee, Hsien-Da Huang.

**Project administration:** Tzu-Hao Chang.

**Supervision:** Wei-Chung Vivian Yang, Tzu-Hao Chang.

**Validation:** Tzong-Yi Lee, Justin Bo-Kai Hsu, Hsien-Da Huang, Tzu-Hao Chang.

**Writing – original draft:** Vijesh Kumar Yadav.
Computational analysis for the ECM involved endometrial cancer progression

Writing – review & editing: Wei-Chung Vivian Yang, Tzu-Hao Chang.

References

1. Hynes RO. The extracellular matrix: not just pretty fibrils. Science (New York, NY). 2009; 326 (5977):1216–9.

2. Mott JD, Werb Z. Regulation of matrix biology by matrix metalloproteinases. Current Opinion in Cell Biology. 2004; 16(5):558–64. https://doi.org/10.1016/j.ceb.2004.07.010 PMID: 15363807

3. Lu P, Weaver VM, Werb Z. The extracellular matrix: a dynamic niche in cancer progression. J Cell Biol. 2012; 196(4):395–406. https://doi.org/10.1083/jcb.201102147 PMID: 22351925

4. Konrad D, Marcin O, Beniamin G, Nikola Z, Robert K, Ewa L, et al. Changes in Expression Pattern of SEMA3F Depending on Endometrial Cancer Grade—Pilot Study. Current Pharmaceutical Biotechnology. 2019; 20(9):727–32. https://doi.org/10.2174/138920202066619061914565 PMID: 31215376

5. Hynes RO. Integrins: Bidirectional, Allosteric Signaling Machines. Cell. 2002; 110(6):673–87. https://doi.org/10.1016/s0092-8674 (02)00971-6 PMID: 12297042

6. Liu L, Zhang SX, Liao W, Farhoodi HP, Wong CW, Chen CC, et al. Mechanore sponsive stem cells to target cancer metastases through biophysical cues. Science Translational Medicine. 2017; 9(400).

7. Wei SC, Fattet L, Tsai JH, Guo Y, Pai VH, Majeski HE, et al. Matrix stiffness drives epithelial-mesenchymal transition and tumour metastasis through a TWIST1-G3BP2 mechanotransduction pathway. Nature cell biology. 2015; 17(5):678–88. https://doi.org/10.1038/ncb3157 PMID: 25893917

8. Ali MY, Chuang CY, Saif MT. Reprogramming cellular phenotype by soft collagen gels. Soft matter. 2014; 10(44):8829–37. https://doi.org/10.1039/c4sm01602e PMID: 25284029

9. Cox TR, Erler JT. Remodeling and homeostasis of the extracellular matrix: implications for fibrotic diseases and cancer. Disease Models & Mechanisms. 2011; 4(2):165–78.

10. Seewaldt V. ECM stiffness paves the way for tumor cells. Nature Medicine. 2014; 20:332. https://doi.org/10.1038/nm.3523 PMID: 24710372

11. Nicolaie KAH, Ezendam NPM, Vos MC, Boll D, Pijnenborg JMA, Kruitwagen RFPM, et al. Follow-up practice in endometrial cancer and the association with patient and hospital characteristics: A study from the population-based PROFILES registry. Gynecologic Oncology. 2013; 129(2):324–31. https://doi.org/10.1016/j.ygyno.2013.02.018 PMID: 23435365

12. Staff N. Endometrial Cancer Incidence Rising in the US and Worldwide. 2017.

13. Sutton G, Axelrod JH, Bundy BN, Roy T, Homesley HD, Malfe tano JH, et al. Whole abdominal radiotherapy in the adjuvant treatment of patients with stage III and IV endometrial cancer: a gynecologic oncology group study. Gynecol Oncol. 2005; 97(3):755–63. https://doi.org/10.1016/j.ygyno.2005.03.011 PMID: 15913742

14. Boll D, Karim-Kos HE, Verhoven R.H.A, Burger CW, Coebergh JW, van de Poll-Franse LV, et al. Increased incidence and improved survival in endometrioid endometrial cancer diagnosed since 1989 in The Netherlands: a population based study. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2013; 166(2):209–14.

15. Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, Vergote I. Endometrial cancer. Lancet (London, England). 2005; 366(9484):491–505.

16. Lax SF, Kurman RJ. A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses. Verhandlungen der Deutschen Gesellschaft fur Pathologie. 1997; 81:228–32. PMID: 9474874

17. Owens GL, Lawrence KM, Jackson TR, Crosbie EJ, Sayan BS, Kitchener HC, et al. Urocortin suppresses endometrial cancer cell migration via CRFR2 and its system components are differentially modulated by estrogen. Cancer Medicine. 2017; 6(2):408–15. https://doi.org/10.1002/cam4.967 PMID: 28109061

18. Onstad MA, Schmandt RE, Lu KH. Addressing the Role of Obesity in Endometrial Cancer Risk, Prevention, and Treatment. Journal of Clinical Oncology. 2016; 34(35):4225–30. https://doi.org/10.1200/JCO.2016.69.4638 PMID: 27903150

19. Matias-Guiu X, Catusus L, Bussaglia E, Lagarda H, Garcia A, Pons C, et al. Molecular pathology of endometrial hyperplasia and carcinoma. Human pathology. 2001; 32(6):569–77. https://doi.org/10.1053/hupa.2001.25929 PMID: 11431710

20. Win AK, Reece JC, Ryan S. Family history and risk of endometrial cancer: a systematic review and meta-analysis. Obstetrics and gynecology. 2015; 125(1):89–98. https://doi.org/10.1097/AOG.0000000000000563 PMID: 25560109
21. Freeman SJ, Aly AM, Kataoka MY, Addley HC, Reinhold C, Sala E. The revised FIGO staging system for uterine malignancies: implications for MR imaging. Radiographics: a review publication of the Radiological Society of North America, Inc. 2012; 32(6):1805–27.

22. Amin MB, Edge SB, American Joint Committee on C. AJCC cancer staging manual 2017.

23. DNA-damaging therapies emerging as possible triple-negative breast cancer therapies. Oncology (Williston Park). 2011; 25(11):1088, 91.

24. Abdel-Fatah TM, Arora A, Moseley PM, Perry C, Rakha EA, Green AR, et al. DNA repair prognostic index modelling reveals an essential role for base excision repair in influencing clinical outcomes in ER negative and triple negative breast cancers. Oncotarget. 2015; 6(26):21964–78. https://doi.org/10.18632/oncotarget.4157 PMID: 26267318

25. Aaboe M, Offersen BV, Christensen A, Andreasen PA. Vitronectin in human breast carcinomas. Biochim Biophys Acta. 2003; 1638(1):72–82. https://doi.org/10.1016/s0925-4439(03)00059-0 PMID: 12757937

26. Grabarek B, Wcislo-Dziadecka D, Gola J, Kruszniowska-Rajs C, Brzezinska-Wcislo L, Zmarzly N, et al. Changes in the Expression Profile of JAK/STAT Signaling Pathway Genes and Mirmas Regulating their Expression Under the Adalimumab Therapy. Curr Pharm Biotechnol. 2018; 19(7):556–65. https://doi.org/10.2174/1389201019666180730094046 PMID: 30058482

27. Barcus CE, Keely PJ, Eliceiri KW, Schuler LA. Stiff collagen matrices increase tumorigenic prolactin signaling in breast cancer cells. J Biol Chem. 2013; 288(18):12722–32. https://doi.org/10.1074/jbc.M112.447631 PMID: 23530035

28. Naba A, Clauser KR, Ding H, Whittaker CA, Carr SA, Hynes RO. The extracellular matrix: Tools and insights for the “omics” era. Matrix Biology. 2016; 49:10–24. https://doi.org/10.1016/j.matbio.2015.06.003 PMID: 26163349

29. Byron A, Humphries JD, Humphries MJ. Defining the extracellular matrix using proteomics. International journal of experimental pathology. 2013; 94(2):75–92. https://doi.org/10.1111/iep.12011 PMID: 23419153

30. Molinary JL, Hurt KJ, Resnick AC, Storm PB, Laroy W, Schnaar RL, et al. UDP-glucuronate decarboxylase, a key enzyme in proteoglycan synthesis: cloning, characterization, and localization. The Journal of biological chemistry. 2002; 277(19):16968–75. https://doi.org/10.1074/jbc.M109316200 PMID: 11877387

31. Gotting C, Kuhn J, Zahn R, Brinkmann T, Kleesiek K. Molecular cloning and expression of human UDP-d-Xylose:proteoglycan core protein beta-d-xylosyltransferase and its first isoform XT-II. Journal of molecular biology. 2000; 304(4):517–28. https://doi.org/10.1006/jmbi.2000.4261 PMID: 11099377

32. Adhikary A, Chakraborty S, Mazumdar M, Ghosh S, Mukherjee S, Manna A, et al. Inhibition of epithelial to mesenchymal transition by E-cadherin up-regulation via repression of slug transcription and inhibition of E-cadherin degradation: dual role of scaffold/matrix attachment region-binding protein 1 (SMAR1) in breast cancer cells. The Journal of biological chemistry. 2014; 289(37):25431–44. https://doi.org/10.1074/jbc.M113.527267 PMID: 25086032

33. Herishanu Y, Gibellini F, Njuguna N, Hazan-Halevy I, Farooqui M, Bern S, et al. Activation of CD44, a receptor for extracellular matrix components, protects chronic lymphocytic leukemia cells from spontaneous and drug induced apoptosis through MCL-1. Leukemia & lymphoma. 2011; 52(9):1758–69.

34. Matsubara T, Araki M, Abe H, Ueda O, Jishage K, Mima A, et al. Bone Morphogenetic Protein 4 and Smad1 Mediate Extracellular Matrix Production in the Development of Diabetic Nephropathy. Diabetes. 2015; 64(8):2978–90. https://doi.org/10.2337/db14-0893 PMID: 25995388

35. Su Y, Yang CY, Li Z, Xu F, Zhang L, Wang F, et al. Smad7 siRNA inhibit expression of extracellular matrix in trabecular meshwork cells treated with TGF-beta2. Molecular vision. 2012; 18:1881–4. PMID: 22876112

36. Weinstein JN, Collisson EA, Mills GB, Shaw KRM, Ozenberger BA, Ellrott K, et al. The cancer genome atlas pan-cancer analysis project. Nature genetics. 2013; 45(10):1113. https://doi.org/10.1038/ng.2764 PMID: 24071849

37. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biology. 2014; 15(12):550. https://doi.org/10.1186/s13059-014-0550-8 PMID: 25516281

38. Gordon A, Glazko G, Qiu X, Yakovlev A. Control of the mean number of false discoveries, Bonferroni and stability of multiple testing. The Annals of Applied Statistics. 2007:179–90.

39. Kramer A, Green J, Pollard J Jr., Tugendreich S. Causal analysis approaches in Ingenuity Pathway Analysis. Bioinformatics. 2014; 30(4):523–30. https://doi.org/10.1093/bioinformatics/btt703 PMID: 24336805
40. Pathman, M., Keerthikumar, S., Ang, C.S., Gangoda, L., Quek, C.Y.J., Williamson, N.A., et al. FunRich: An open access standalone functional enrichment and interaction network analysis tool. PROTEOMICS, 2015; 15(15):2597–601. https://doi.org/10.1002/pmic.201400515 PMID: 25921073
41. Langfelder, P., Horvath, S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics. 2008; 9(1):559.
42. Desgrosellier, J.S., Cheresh, D.A. Integrins in cancer: biological implications and therapeutic opportunities. Nature Reviews Cancer. 2010; 10(1):9. https://doi.org/10.1038/nrc2748 PMID: 20029421
43. Selvamurugan, N., Kwok, S., Partridge, N.C. Smad3 interacts with JunB and Cbfα1/Runx2 for transforming growth factor-beta1-stimulated collagenase-3 expression in human breast cancer cells. The Journal of biological chemistry. 2004; 279(26):27764–73. https://doi.org/10.1074/jbc.M312870200 PMID: 15084595
44. Kuo, Y.C., Su, C.H., Liu, C.Y., Chen, T.H., Chen, C.P., Wang, H.S. Transforming growth factor-beta induces CD44 cleavage that promotes migration of MDA-MB-435s cells through the up-regulation of membrane type 1-matrix metalloproteinase. International journal of cancer. 2009; 124(11):2568–76. https://doi.org/10.1002/ijc.24263 PMID: 19243022
45. Moiseeva, E.P., Straatman, K.R., Leyland, M.L., Bradding, P. CDAM1 controls actin cytoskeleton assembly and regulates extracellular matrix adhesion in human mast cells. PLoS one. 2014; 9(1):e85980. https://doi.org/10.1371/journal.pone.0085980 PMID: 24465823
46. Owens, P., Pickup, M.W., Novitskiy, S.V., Chytil, A., Gorska, A.E., Aakre, M.E., et al. Disruption of bone morphogenetic protein receptor 2 (BMPR2) in mammary tumors promotes metastases through cell autonomous and paracrine mediators. Proceedings of the National Academy of Sciences. 2012; 109(8):2814–9.
47. Page, J.M., Merkel, A.R., Ruppender, N.S., Guo, R., Dadwal, U.C., Cannonier, S., et al. Matrix rigidity regulates the transition of tumor cells to a bone-destructive phenotype through integrin β3a and TGF-β1 receptor type II. Biomaterials. 2015; 64:33–44. https://doi.org/10.1016/j.biomaterials.2015.06.026 PMID: 26115412
48. Cuellar, K., Chong, H., Hubbell, S.M., Hinks, M.E. Biosynthesis of chondroitin and heparan sulfate in chimeric hamster ovarian cells depends on xylosyltransferase II. The Journal of biological chemistry. 2007; 282(6):5195–200. https://doi.org/10.1074/jbc.M61048200 PMID: 17189266
49. Fini, M.A., Orchard-Webb, D., Kosmider, B., Amon, J.D., Kelland, R., Shibao, G., et al. Migratory activity of human breast cancer cells is modulated by differential expression of xanthine oxidoreductase. Journal of cellular biochemistry. 2008; 105(4):1008–26. https://doi.org/10.1002/jcb.21901 PMID: 18767115
50. Lim, S.B., Tan, S.J., Lim, W-T., Lim, C.T. An extracellular matrix-related prognostic and predictive indicator for early-stage non-small cell lung cancer. Nature Communications. 2017; 8(1):1734. https://doi.org/10.1038/s41467-017-01430-6 PMID: 29170406
51. Le, Y., Huang, K., Gao, C., Lau, Q.C., Pan, H., Xie, K., et al. Proteomics Identification of ITGB3 as a Key Regulator in Reactive Oxygen Species-induced Migration of Colonorectal Cancer Cells. Molecular & Cellular Proteomics: MCP. 2011; 10(10):M110.005397.
52. Georgiou, G.K., Igglezou, M., Sainis, I., Vareli, K., Batsis, H., Briasoulis, E., et al. Impact of breast cancer surgery on angiogenesis circulating biomarkers: a prospective longitudinal study. World Journal of Surgical Oncology. 2013; 11(1):213.
53. Du, X.L., Jiang, T., Zhao, W.B., Wang, F., Wang, G.L., Cui, M., et al. Gene alterations in tumor-associated endothelial cells from endometrial cancer. Int J Mol Med. 2008; 22(5):619–32. PMID: 18949382
54. Ezumi, Y., Uchiyama, T., Takayama, H. Molecular Cloning, Genomic Structure, Chromosomal Localization, and Alternative Splice Forms of the Platelet Collagen Receptor Glycoprotein VI. Biochemical and Biophysical Research Communications. 2000; 277(1):27–36. https://doi.org/10.1006/BBRC.2000.3624 PMID: 11027634
55. Kopp, H.G., Placke, T., Salih, H.R. Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity. Cancer research. 2009; 69(19):7775–83. https://doi.org/10.1158/0008-5472.CAN-09-2123 PMID: 19798039
56. Bellucci, S., Huisse, M.G., Bova, B., Hainaud, P., Robert, A., Fauvel-Lafeve, F., et al. Defective collagen-induced platelet activation in two patients with malignant haemopathies is related to a defect in the GPVI-coupled signalling pathway. Thrombosis and haemostasis. 2005; 93(1):130–8. https://doi.org/10.1160/TH04-05-0312 PMID: 15630503
57. Jain, S., Russell, S., Ware, J. Platelet glycoprotein VI facilitates experimental lung metastasis in syngenic mouse models. Journal of thrombosis and haemostasis: JTH. 2009; 7(10):1713–7. https://doi.org/10.1111/j.1538-7836.2009.03559.x PMID: 19624454
58. Abdel-Fatah, T.M., Russell, R., Albarakati, N., Maloney, D.J., Dorjsuren, D., Rueda, O.M., et al. Genomic and protein expression analysis reveals flap endonuclease 1 (FEN1) as a key biomarker in breast and...
ovarian cancer. Mol Oncol. 2014; 8(7):1326–38. https://doi.org/10.1016/j.molonc.2014.04.009 PMID: 24880630

59. Yen C-F, Wang H-S, Lee C-L, Liao S-K. Roles of integrin-linked kinase in cell signaling and its perspectives as a therapeutic target. Gynecology and Minimally Invasive Therapy. 2014; 3(3):67–72.

60. Tan C, Cretu-Henqueurt S, Troussard A, Fazli L, Costello P, Sutton K, et al. Regulation of tumor angiogenesis by integrin-linked kinase (ILK). Cancer Cell. 2004; 5(1):79–90. https://doi.org/10.1016/s1535-6108(03)00281-2 PMID: 14749128

61. Milovanović J, Todorović-Raković N, Radulović M. Interleukin-6 and interleukin-8 serum levels in prognosis of hormone-dependent breast cancer. Cytokine. 2018.

62. Kenny HA, Kaur S, Coussens LM, Lengyel E. The initial steps of ovarian cancer cell metastasis are mediated by MMP-2 cleavage of vitronectin and fibronectin. The Journal of clinical investigation. 2008; 118(4):1367–79. https://doi.org/10.1172/JCI33775 PMID: 18340378

63. Lin TH, Liu HH, Tsai TH, Chen CC, Hsieh TF, Lee SS, et al. CCL2 increases alphavbeta3 integrin expression and subsequently promotes prostate cancer migration. Biochim Biophys Acta. 2013; 1830(10):4917–27. https://doi.org/10.1016/j.bbadis.2013.06.033 PMID: 23845726

64. Xiong S, Klausen C, Cheng JC, Zhu H, Leung PC. Activin B induces human endometrial cancer cell adhesion, migration and invasion by up-regulating integrin beta1 via SMAD2/3 signaling. Oncotarget. 2015; 6(31):31659–73. https://doi.org/10.18632/oncotarget.5229 PMID: 26384307

65. Categorization of triple-negative breast cancer patients will help in targeted therapy selection. Oncology (Williston Park). 2011; 25(9):849.

66. Abecassis J, Millon-Collard R, Klein-Soyer C, Nicora F, Fricker JP, Beretz A, et al. Adhesion of human breast cancer cell line MCF-7 to human vascular endothelial cells in culture. Enhancement by activated platelets. Int J Cancer. 1987; 40(4):525–31. https://doi.org/10.1002/ijc.2910400416 PMID: 3666990

67. Shen Y, Shen R, Ge L, Zhu Q, Li F. Fibrillar type I collagen matrices enhance metastasis/invasion of ovarian epithelial cancer via beta1 integrin and PTEN signals. International journal of gynecological cancer: official journal of the International Gynecological Cancer Society. 2012; 22(8):1316–24.

68. Sun H, Wang X, Zhang Y, Che X, Liu Z, Zhang L, et al. Biglycan enhances the ability of migration and invasion in endometrial cancer. Archives of gynecology and obstetrics. 2016; 293(2):429–38. https://doi.org/10.1007/s00404-015-3844-5 PMID: 26275380

69. Yusuf N, Inagaki T, Kusunoki S, Okabe H, Yamada I, Matsumoto A, et al. SPARC was overexpressed in eutopic and endometrioid endometrial carcinoma. International journal of gynecological cancer. 2016; 21(4):973–8.

70. Torres PB, Florio P, Galleri L, Reis FM, Borges LE, Petraglia F, Activin A, activin receptor type II, nodal, and cripto mRNA are expressed by eutopic and ectopic endometrial women with ovarian endometriosis. Reproductive sciences (Thousand Oaks, Calif). 2009; 16(8):727–33.

71. Seki N, Kodama J, Hashimoto I, Hongo A, Yoshinouchi M, Kudo T. Thrombospondin-1 and -2 motes metastatic cancer cell interaction with the endothelium. The EMBO journal. 2017; 36(16):2373–89. https://doi.org/10.15252/embj.201694912 PMID: 28694244

72. Lu P, Weaver VM, Werb Z. The extracellular matrix: A dynamic niche in cancer progression. The Journal of cell biology. 2012; 196(4):395–406. https://doi.org/10.1083/jcb.201102147 PMID: 22351925

73. Du J, Zu Y, Li J, Du S, Xu Y, Zhang L, et al. Extracellular matrix stiffness dictates Wnt expression through integrin pathway. Scientific Reports. 2016; 6:20395. https://doi.org/10.1038/srep20395 PMID: 26854061

74. Parikh D, Stack M, Wang H. Matrix Stiffness Regulates the Fate of Breast Cancer Cells. Biophysical Journal. 2018; 114(3):651a.
79. Alexopoulos LG, Youn I, Bonaldo P, Guilak F. Developmental and osteoarthritic changes in Col6a1-knockout mice: biomechanics of type VI collagen in the cartilage pericellular matrix. Arthritis and rheumatism. 2009; 60(3):771–9. https://doi.org/10.1002/art.24293 PMID: 19248115

80. Giménez A, Duch P, Puig M, Gabasa M, Xaubet A, Alcaraz J. Dysregulated Collagen Homeostasis by Matrix Stiffening and TGF-β1 in Fibroblasts from Idiopathic Pulmonary Fibrosis Patients: Role of FAK/Akt. International journal of molecular sciences. 2017; 18(11):2431.

81. Karamichos D, Brown RA, Mudera V. Collagen stiffness regulates cellular contraction and matrix remodeling gene expression. Journal of biomedical materials research Part A. 2007; 83(3):887–94. https://doi.org/10.1002/jbm.a.31423 PMID: 17567861